Industry News (Influenza Vaccine)

Preliminary Phase II Results from Worldwide Influenza Collaboration Announced

Published in Vaccine Weekly, September 6th, 1999

BioCryst Pharmaceuticals, Inc., Birmingham, Alabama, announced preliminary results from a Phase II clinical study of RWJ-270201, a neuraminidase inhibitor, conducted by the R.W. Johnson Pharmaceutical Research Institute (PRI), a Johnson & Johnson company.

PRI conducted a Phase II, placebo-controlled, randomized study of healthy volunteers infected with a susceptible strain of Influenza A and has provided preliminary results to BioCryst. The primary efficacy endpoint was the reduction in viral titers in infected subjects. Preliminary results showed a statistically significant result for the primary endpoint and evaluation of safety showed that the drug was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry